ArticleTrials2018

Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial.

Guillaume Mouillet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.